A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.

The aim of this protocol is to find out about the safety and effectiveness of M2951 in participants with relapsing multiple sclerosis. Participants were placed into 1 of 3 groups to receive M2951, placebo or tecfidera for 24 weeks. After 24 weeks, the participants on placebo were given M2951.

本试验方案旨在评估M2951用于复发型多发性硬化症（relapsing multiple sclerosis）受试者的安全性与有效性。受试者被随机分配至3个组别之一，分别接受M2951、安慰剂或富马酸二甲酯（Tecfidera）治疗，疗程为24周。治疗24周后，原安慰剂组的受试者将被给予M2951进行后续治疗。